|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MPHOSPH6 |
Gene summary for MPHOSPH6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MPHOSPH6 | Gene ID | 10200 |
| Gene name | M-phase phosphoprotein 6 | |
| Gene Alias | MPP | |
| Cytomap | 16q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000460 | UniProtAcc | Q99547 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10200 | MPHOSPH6 | GSM4909282 | Human | Breast | IDC | 1.09e-04 | 2.79e-01 | -0.0288 |
| 10200 | MPHOSPH6 | GSM4909285 | Human | Breast | IDC | 4.39e-03 | -9.23e-02 | 0.21 |
| 10200 | MPHOSPH6 | GSM4909286 | Human | Breast | IDC | 8.63e-04 | -1.82e-01 | 0.1081 |
| 10200 | MPHOSPH6 | GSM4909290 | Human | Breast | IDC | 7.64e-24 | 6.29e-01 | 0.2096 |
| 10200 | MPHOSPH6 | GSM4909293 | Human | Breast | IDC | 1.07e-02 | -1.42e-01 | 0.1581 |
| 10200 | MPHOSPH6 | GSM4909297 | Human | Breast | IDC | 4.05e-02 | -1.30e-01 | 0.1517 |
| 10200 | MPHOSPH6 | GSM4909298 | Human | Breast | IDC | 5.53e-03 | 1.91e-01 | 0.1551 |
| 10200 | MPHOSPH6 | GSM4909304 | Human | Breast | IDC | 7.80e-10 | 3.50e-01 | 0.1636 |
| 10200 | MPHOSPH6 | GSM4909306 | Human | Breast | IDC | 2.86e-02 | -1.78e-01 | 0.1564 |
| 10200 | MPHOSPH6 | GSM4909307 | Human | Breast | IDC | 2.23e-04 | -2.38e-01 | 0.1569 |
| 10200 | MPHOSPH6 | GSM4909308 | Human | Breast | IDC | 5.47e-03 | -2.68e-01 | 0.158 |
| 10200 | MPHOSPH6 | GSM4909311 | Human | Breast | IDC | 1.43e-06 | -2.33e-01 | 0.1534 |
| 10200 | MPHOSPH6 | GSM4909319 | Human | Breast | IDC | 1.60e-11 | -2.59e-01 | 0.1563 |
| 10200 | MPHOSPH6 | GSM4909321 | Human | Breast | IDC | 3.07e-07 | -2.39e-01 | 0.1559 |
| 10200 | MPHOSPH6 | brca1 | Human | Breast | Precancer | 9.48e-05 | 2.04e-01 | -0.0338 |
| 10200 | MPHOSPH6 | brca2 | Human | Breast | Precancer | 2.34e-10 | 3.53e-01 | -0.024 |
| 10200 | MPHOSPH6 | brca3 | Human | Breast | Precancer | 5.58e-04 | 2.96e-03 | -0.0263 |
| 10200 | MPHOSPH6 | NCCBC6 | Human | Breast | DCIS | 1.84e-02 | 3.55e-01 | 0.2095 |
| 10200 | MPHOSPH6 | P2 | Human | Breast | IDC | 4.66e-17 | 6.68e-01 | 0.21 |
| 10200 | MPHOSPH6 | DCIS2 | Human | Breast | DCIS | 3.87e-41 | -2.17e-02 | 0.0085 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
| GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
| GO:00063646 | Breast | Precancer | rRNA processing | 35/1080 | 225/18723 | 7.90e-08 | 4.60e-06 | 35 |
| GO:00160726 | Breast | Precancer | rRNA metabolic process | 36/1080 | 236/18723 | 8.59e-08 | 4.84e-06 | 36 |
| GO:00344705 | Breast | Precancer | ncRNA processing | 42/1080 | 395/18723 | 9.91e-05 | 1.83e-03 | 42 |
| GO:00346604 | Breast | Precancer | ncRNA metabolic process | 45/1080 | 485/18723 | 1.15e-03 | 1.26e-02 | 45 |
| GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
| GO:004225414 | Breast | IDC | ribosome biogenesis | 52/1434 | 299/18723 | 1.90e-08 | 1.32e-06 | 52 |
| GO:000636414 | Breast | IDC | rRNA processing | 35/1434 | 225/18723 | 4.59e-05 | 1.03e-03 | 35 |
| GO:001607214 | Breast | IDC | rRNA metabolic process | 36/1434 | 236/18723 | 5.48e-05 | 1.17e-03 | 36 |
| GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
| GO:004225423 | Breast | DCIS | ribosome biogenesis | 52/1390 | 299/18723 | 6.73e-09 | 5.44e-07 | 52 |
| GO:000636422 | Breast | DCIS | rRNA processing | 35/1390 | 225/18723 | 2.41e-05 | 5.62e-04 | 35 |
| GO:001607222 | Breast | DCIS | rRNA metabolic process | 36/1390 | 236/18723 | 2.86e-05 | 6.42e-04 | 36 |
| GO:003447011 | Breast | DCIS | ncRNA processing | 44/1390 | 395/18723 | 4.56e-03 | 3.49e-02 | 44 |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| GO:004225426 | Esophagus | HGIN | ribosome biogenesis | 101/2587 | 299/18723 | 8.74e-19 | 4.03e-16 | 101 |
| GO:001607219 | Esophagus | HGIN | rRNA metabolic process | 72/2587 | 236/18723 | 2.26e-11 | 2.56e-09 | 72 |
| GO:000636419 | Esophagus | HGIN | rRNA processing | 69/2587 | 225/18723 | 4.53e-11 | 5.04e-09 | 69 |
| GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030186 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
| hsa0301811 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
| hsa0301821 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
| hsa0301831 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
| hsa030184 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
| hsa030185 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
| hsa0301810 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
| hsa0301815 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MPHOSPH6 | SNV | Missense_Mutation | novel | c.265C>T | p.Leu89Phe | p.L89F | Q99547 | protein_coding | tolerated(0.47) | benign(0.11) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MPHOSPH6 | SNV | Missense_Mutation | novel | c.70N>A | p.Asp24Asn | p.D24N | Q99547 | protein_coding | deleterious(0.02) | probably_damaging(0.96) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MPHOSPH6 | insertion | Nonsense_Mutation | novel | c.68_69insAAAATGCTCAACCTAAT | p.Asp24LysfsTer5 | p.D24Kfs*5 | Q99547 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MPHOSPH6 | SNV | Missense_Mutation | novel | c.33N>C | p.Lys11Asn | p.K11N | Q99547 | protein_coding | deleterious(0.01) | benign(0.119) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| MPHOSPH6 | SNV | Missense_Mutation | c.37C>A | p.Leu13Ile | p.L13I | Q99547 | protein_coding | tolerated(0.17) | possibly_damaging(0.566) | TCGA-CM-4752-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MPHOSPH6 | SNV | Missense_Mutation | c.125N>T | p.Glu42Val | p.E42V | Q99547 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
| MPHOSPH6 | SNV | Missense_Mutation | c.205G>T | p.Asp69Tyr | p.D69Y | Q99547 | protein_coding | deleterious(0.01) | probably_damaging(0.926) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPHOSPH6 | SNV | Missense_Mutation | c.283C>T | p.His95Tyr | p.H95Y | Q99547 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPHOSPH6 | SNV | Missense_Mutation | novel | c.434N>C | p.Asp145Ala | p.D145A | Q99547 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| MPHOSPH6 | SNV | Missense_Mutation | novel | c.84G>T | p.Lys28Asn | p.K28N | Q99547 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |